{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T16:05:17Z","timestamp":1787501117330,"version":"build-2736575974"},"reference-count":85,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["fertstertreviews.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["F&amp;S Reviews"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.xfnr.2020.11.001","type":"journal-article","created":{"date-parts":[[2020,11,16]],"date-time":"2020-11-16T21:16:40Z","timestamp":1605561400000},"page":"32-42","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Exogenous testosterone replacement therapy versus raising endogenous testosterone levels: current and future prospects"],"prefix":"10.1016","volume":"2","author":[{"given":"Kajal","family":"Khodamoradi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahra","family":"Khosravizadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madhu","family":"Parmar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2238-6752","authenticated-orcid":false,"given":"Manish","family":"Kuchakulla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ranjith","family":"Ramasamy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3143-6387","authenticated-orcid":false,"given":"Himanshu","family":"Arora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xfnr.2020.11.001_bib1","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s11934-018-0816-x","article-title":"Novel therapy for male hypogonadism","volume":"19","author":"Carrasquillo","year":"2018","journal-title":"Curr Urol Rep"},{"key":"10.1016\/j.xfnr.2020.11.001_bib2","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1038\/sj.ijir.3901365","article-title":"Male hypogonadism. Part II: etiology, pathophysiology, and diagnosis","volume":"18","author":"Seftel","year":"2006","journal-title":"Int J Impot Res"},{"key":"10.1016\/j.xfnr.2020.11.001_bib3","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.eururo.2017.02.022","article-title":"European Association of Urology position statement on the role of the urologist in the management of male hypogonadism and testosterone therapy","volume":"72","author":"Mirone","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.xfnr.2020.11.001_bib4","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1016\/S0140-6736(13)61126-5","article-title":"Male hypogonadism","volume":"383","author":"Basaria","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.xfnr.2020.11.001_bib5","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.juro.2018.03.115","article-title":"Evaluation and management of testosterone deficiency: AUA guideline","volume":"200","author":"Mulhall","year":"2018","journal-title":"J Urol"},{"key":"10.1016\/j.xfnr.2020.11.001_bib6","first-page":"427","article-title":"The benefits and risks of testosterone replacement therapy: a review","volume":"5","author":"Bassil","year":"2009","journal-title":"Ther Clin Risk Manag"},{"key":"10.1016\/j.xfnr.2020.11.001_bib7","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.amjmed.2010.12.027","article-title":"Testosterone deficiency","volume":"124","author":"Traish","year":"2011","journal-title":"Am J Med"},{"key":"10.1016\/j.xfnr.2020.11.001_bib8","doi-asserted-by":"crossref","first-page":"183","DOI":"10.21037\/tau.2016.11.16","article-title":"Testosterone deficiency in adults and corresponding treatment patterns across the globe","volume":"6","author":"Anaissie","year":"2017","journal-title":"Transl Androl Urol"},{"key":"10.1016\/j.xfnr.2020.11.001_bib9","first-page":"1","article-title":"Prevalence of testosterone deficiency among aging men with and without morbidities","volume":"1","author":"Erenpreiss","year":"2019","journal-title":"Aging Male"},{"key":"10.1016\/j.xfnr.2020.11.001_bib10","doi-asserted-by":"crossref","first-page":"192","DOI":"10.4103\/1008-682X.122336","article-title":"Late-onset hypogonadism: current concepts and controversies of pathogenesis, diagnosis and treatment","volume":"16","author":"Huhtaniemi","year":"2014","journal-title":"Asian J Androl"},{"key":"10.1016\/j.xfnr.2020.11.001_bib11","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa0911101","article-title":"Identification of late-onset hypogonadism in middle-aged and elderly men","volume":"363","author":"Wu","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.xfnr.2020.11.001_bib12","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1111\/and.12305","article-title":"Male hypogonadism and metabolic syndrome","volume":"47","author":"Naifar","year":"2015","journal-title":"Andrologia"},{"key":"10.1016\/j.xfnr.2020.11.001_bib13","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.beem.2014.09.008","article-title":"Current topics in testosterone replacement of hypogonadal men","volume":"29","author":"Nieschlag","year":"2015","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"10.1016\/j.xfnr.2020.11.001_bib14","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.metabol.2018.03.007","article-title":"Testosterone replacement therapy: for whom, when and how?","volume":"86","author":"Tsametis","year":"2018","journal-title":"Metabolism"},{"key":"10.1016\/j.xfnr.2020.11.001_bib15","first-page":"366","article-title":"Plasma androgen levels in men after oral administration of testosterone or testosterone undecanoate","volume":"79","author":"Nieschlag","year":"1975","journal-title":"Acta Endocrinol"},{"key":"10.1016\/j.xfnr.2020.11.001_bib16","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1210\/clinem\/dgaa238","article-title":"A new oral testosterone undecanoate formulation restores testosterone to normal concentrations in hypogonadal men","volume":"105","author":"Swerdloff","year":"2020","journal-title":"J Clin Endocrinol Metabol"},{"key":"10.1016\/j.xfnr.2020.11.001_bib17","first-page":"262","article-title":"Liver damage from long-term methyltestosterone","volume":"2","author":"Westaby","year":"1977","journal-title":"Lancet"},{"key":"10.1016\/j.xfnr.2020.11.001_bib18","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/S0140-6736(73)91384-6","article-title":"Androgenic-anabolic steroid therapy and hepatocellular carcinoma","volume":"1","author":"Henderson","year":"1973","journal-title":"Lancet"},{"key":"10.1016\/j.xfnr.2020.11.001_bib19","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1111\/j.1368-5031.2004.00383.x","article-title":"Striant SR: a novel, effective and convenient testosterone therapy for male hypogonadism","volume":"58","author":"Korbonits","year":"2004","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.xfnr.2020.11.001_bib20","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1111\/j.1464-410X.2011.10837.x","article-title":"The long-term efficacy and safety of a testosterone mucoadhesive buccal tablet in testosterone-deficient men","volume":"110","author":"Dinsmore","year":"2012","journal-title":"BJU Int"},{"key":"10.1016\/j.xfnr.2020.11.001_bib21","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1530\/eje.0.1400414","article-title":"Intramuscular injection of testosterone undecanoate for the treatment of male hypogonadism: phase I studies","volume":"140","author":"Behre","year":"1999","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.xfnr.2020.11.001_bib22","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1210\/jcem-63-6-1361","article-title":"Pharmacokinetic properties of testosterone propionate in normal men","volume":"63","author":"Fujioka","year":"1986","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.xfnr.2020.11.001_bib23","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1530\/EJE-14-0891","article-title":"Complications of injectable testosterone undecanoate in routine clinical practice","volume":"172","author":"Middleton","year":"2015","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.xfnr.2020.11.001_bib24","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1093\/oxfordjournals.humrep.a136051","article-title":"Tolerability of intramuscular injections of testosterone ester in oil vehicle","volume":"10","author":"Mackey","year":"1995","journal-title":"Hum Reprod"},{"key":"10.1016\/j.xfnr.2020.11.001_bib25","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1093\/humrep\/den372","article-title":"Hyperandrogenism after transfer of topical testosterone gel: case report and review of published and unpublished studies","volume":"24","author":"de Ronde","year":"2009","journal-title":"Hum Reprod"},{"key":"10.1016\/j.xfnr.2020.11.001_bib26","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1038\/sj.ijir.3901366","article-title":"Testosterone replacement therapy for male hypogonadism: part III. Pharmacologic and clinical profiles, monitoring, safety issues, and potential future agents","volume":"19","author":"Seftel","year":"2007","journal-title":"Int J Impot Res"},{"key":"10.1016\/j.xfnr.2020.11.001_bib27","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1046\/j.1365-2265.1999.00827.x","article-title":"Extrusion of testosterone pellets: a randomized controlled clinical study","volume":"51","author":"Kelleher","year":"1999","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.xfnr.2020.11.001_bib28","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1111\/j.1365-2265.2009.03744.x","article-title":"Randomized cross-over clinical trial of injectable vs. implantable depot testosterone for maintenance of testosterone replacement therapy in androgen deficient men","volume":"73","author":"Fennell","year":"2010","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.xfnr.2020.11.001_bib29","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1210\/js.2019-00183","article-title":"Efficacy of nasal testosterone gel (Natesto\u00ae) stratified by baseline endogenous testosterone levels","volume":"3","author":"Gronski","year":"2019","journal-title":"J Endocr Soc"},{"key":"10.1016\/j.xfnr.2020.11.001_bib30","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.euf.2018.08.009","article-title":"Natesto effects on reproductive hormones and semen parameters: results from an ongoing single-center, investigator-initiated phase IV clinical trial","volume":"4","author":"Masterson","year":"2018","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.xfnr.2020.11.001_bib31","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1097\/JU.0000000000001078","article-title":"Effect of natesto on reproductive hormones, semen parameters and hypogonadal symptoms: a single-center, open-label, single-arm trial","volume":"204","author":"Ramasamy","year":"2020","journal-title":"J Urol"},{"key":"10.1016\/j.xfnr.2020.11.001_bib32","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1111\/bju.13337","article-title":"Oral enclomiphene citrate raises testosterone and preserves sperm counts in obese hypogonadal men, unlike topical testosterone: restoration instead of replacement","volume":"117","author":"Kim","year":"2016","journal-title":"BJU Int"},{"key":"10.1016\/j.xfnr.2020.11.001_bib33","first-page":"955","article-title":"World Health Organization Task Force on methods for the regulation of male fertility","volume":"336","author":"Contraceptive efficacy of testosterone-induced azoospermia in normal men","year":"1990","journal-title":"Lancet"},{"key":"10.1016\/j.xfnr.2020.11.001_bib34","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1111\/andr.12137","article-title":"Natesto\u2122, a novel testosterone nasal gel, normalizes androgen levels in hypogonadal men","volume":"4","author":"Rogol","year":"2016","journal-title":"Andrology"},{"key":"10.1016\/j.xfnr.2020.11.001_bib35","doi-asserted-by":"crossref","first-page":"E349","DOI":"10.5489\/cuaj.4898","article-title":"Phase 1 pharmacokinetics and phase 3 efficacy of testosterone nasal gel in subjects with seasonal allergies","volume":"12","author":"Rogol","year":"2018","journal-title":"Can Urol Assoc J"},{"key":"10.1016\/j.xfnr.2020.11.001_bib36","doi-asserted-by":"crossref","first-page":"734","DOI":"10.2164\/jandrol.107.002790","article-title":"Intratesticular androgens and spermatogenesis during severe gonadotropin suppression induced by male hormonal contraceptive treatment","volume":"28","author":"Page","year":"2007","journal-title":"J Androl"},{"key":"10.1016\/j.xfnr.2020.11.001_bib37","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/ncpendmet0069","article-title":"Drug insight: recent advances in male hormonal contraception","volume":"2","author":"Amory","year":"2006","journal-title":"Nat Clin Pract Endocrinol Metab"},{"key":"10.1016\/j.xfnr.2020.11.001_bib38","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s11255-010-9879-4","article-title":"Importance of hypogonadism and testosterone replacement therapy in current urologic practice: a review","volume":"44","author":"Hellstrom","year":"2012","journal-title":"Int Urol Nephrol"},{"key":"10.1016\/j.xfnr.2020.11.001_bib39","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/j.juro.2016.10.063","article-title":"Trends in Testosterone replacement therapy use from 2003 to 2013 among reproductive-age men in the United States","volume":"197","author":"Rao","year":"2017","journal-title":"J Urol"},{"key":"10.1016\/j.xfnr.2020.11.001_bib40","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.fertnstert.2013.09.003","article-title":"Testosterone use in the male infertility population: prescribing patterns and effects on semen and hormonal parameters","volume":"101","author":"Samplaski","year":"2014","journal-title":"Fertil Steril"},{"key":"10.1016\/j.xfnr.2020.11.001_bib41","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/j.juro.2011.10.137","article-title":"Empirical medical therapy for idiopathic male infertility: a survey of the American Urological Association","volume":"187","author":"Ko","year":"2012","journal-title":"J Urol"},{"key":"10.1016\/j.xfnr.2020.11.001_bib42","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1016\/j.urology.2014.12.052","article-title":"Medical testosterone: an iatrogenic cause of male infertility and a growing problem","volume":"85","author":"Kolettis","year":"2015","journal-title":"Urology"},{"key":"10.1016\/j.xfnr.2020.11.001_bib43","doi-asserted-by":"crossref","first-page":"S348","DOI":"10.21037\/tau.2018.04.11","article-title":"Indications for the use of human chorionic gonadotropic hormone for the management of infertility in hypogonadal men","volume":"7","author":"Lee","year":"2018","journal-title":"Transl Androl Urol"},{"key":"10.1016\/j.xfnr.2020.11.001_bib44","doi-asserted-by":"crossref","first-page":"859","DOI":"10.21037\/tau.2016.08.03","article-title":"Testosterone replacement in the infertile man","volume":"5","author":"Majzoub","year":"2016","journal-title":"Transl Androl Urol"},{"key":"10.1016\/j.xfnr.2020.11.001_bib45","first-page":"106","article-title":"Exogenous testosterone: a preventable cause of male infertility","volume":"2","author":"Crosnoe","year":"2013","journal-title":"Transl Androl Urol"},{"key":"10.1016\/j.xfnr.2020.11.001_bib46","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.aju.2017.11.011","article-title":"Systematic review of hormone replacement therapy in the infertile man","volume":"16","author":"El Meliegy","year":"2018","journal-title":"Arab J Urol"},{"key":"10.1016\/j.xfnr.2020.11.001_bib47","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.fertnstert.2014.12.122","article-title":"On-label and off-label drugs used in the treatment of male infertility","volume":"103","author":"Chehab","year":"2015","journal-title":"Fertil Steril"},{"key":"10.1016\/j.xfnr.2020.11.001_bib48","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1111\/j.1439-0272.2011.01163.x","article-title":"Beneficial effect of tamoxifen on sperm recovery in infertile men with nonobstructive azoospermia","volume":"44","author":"Moein","year":"2012","journal-title":"Andrologia"},{"key":"10.1016\/j.xfnr.2020.11.001_bib49","first-page":"1437","article-title":"Selective estrogen receptor modulators: tissue specificity and clinical utility","volume":"9","author":"Martinkovich","year":"2014","journal-title":"Clin Interv Aging"},{"key":"10.1016\/j.xfnr.2020.11.001_bib50","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.maturitas.2010.05.009","article-title":"SERMs: progress and future perspectives","volume":"67","author":"Pickar","year":"2010","journal-title":"Maturitas"},{"key":"10.1016\/j.xfnr.2020.11.001_bib51","unstructured":"Dohle G, Arver S, Bettocchi C, Jones T, Kliesch S, Punab M. EAU guidelines on male hypogonadism. European Association of Urology, Arnhem, The Netherlands. Available at http:\/\/www.uroweb.org\/guidelines\/online-guidelines\/. Accessed March 20, 2020."},{"key":"10.1016\/j.xfnr.2020.11.001_bib52","doi-asserted-by":"crossref","first-page":"245","DOI":"10.5527\/wjn.v4.i2.245","article-title":"Treatment of hypogonadotropic male hypogonadism: case-based scenarios","volume":"4","author":"Crosnoe-Shipley","year":"2015","journal-title":"World J Nephrol"},{"key":"10.1016\/j.xfnr.2020.11.001_bib53","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.juro.2012.09.043","article-title":"Concomitant intramuscular human chorionic gonadotropin preserves spermatogenesis in men undergoing testosterone replacement therapy","volume":"189","author":"Hsieh","year":"2013","journal-title":"J Urol"},{"key":"10.1016\/j.xfnr.2020.11.001_bib54","doi-asserted-by":"crossref","first-page":"2595","DOI":"10.1210\/jc.2004-0802","article-title":"Low-dose human chorionic gonadotropin maintains intratesticular testosterone in normal men with testosterone-induced gonadotropin suppression","volume":"90","author":"Coviello","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.xfnr.2020.11.001_bib55","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1590\/S0041-87812004000600011","article-title":"Effects of medical therapy, alcohol, smoking, and endocrine disruptors on male infertility","volume":"59","author":"Pasqualotto","year":"2004","journal-title":"Rev Hosp Clin Fac Med Sao Paulo"},{"key":"10.1016\/j.xfnr.2020.11.001_bib56","first-page":"82","article-title":"Aromatase inhibitors in the treatment of oligozoospermic or azoospermic men: a systematic review of randomized controlled trials","volume":"20","author":"Ribeiro","year":"2016","journal-title":"JBRA Assist Reprod"},{"key":"10.1016\/j.xfnr.2020.11.001_bib57","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1016\/S0026-0495(03)00186-0","article-title":"Reversal of the hypogonadotropic hypogonadism of obese men by administration of the aromatase inhibitor testolactone","volume":"52","author":"Zumoff","year":"2003","journal-title":"Metabolism"},{"key":"10.1016\/j.xfnr.2020.11.001_bib58","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1210\/jc.2003-031467","article-title":"Effects of aromatase inhibition in elderly men with low or borderline-low serum testosterone levels","volume":"89","author":"Leder","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.xfnr.2020.11.001_bib59","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.mce.2017.06.013","article-title":"Development of selective androgen receptor modulators (SARMs)","volume":"465","author":"Narayanan","year":"2018","journal-title":"Mol Cell Endocrinol"},{"key":"10.1016\/j.xfnr.2020.11.001_bib60","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.sxmr.2018.09.006","article-title":"Selective androgen receptor modulators: current knowledge and clinical applications","volume":"7","author":"Solomon","year":"2019","journal-title":"Sex Med Rev"},{"key":"10.1016\/j.xfnr.2020.11.001_bib61","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1210\/en.2006-0793","article-title":"An orally active selective androgen receptor modulator is efficacious on bone, muscle, and sex function with reduced impact on prostate","volume":"148","author":"Miner","year":"2007","journal-title":"Endocrinology"},{"key":"10.1016\/j.xfnr.2020.11.001_bib62","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1210\/en.2008-0674","article-title":"Preclinical characterization\u00a0of a (S)-N-(4-cyano-3-trifluoromethyl-phenyl)-3-(3-fluoro, 4-chlorophenoxy)-2-hydroxy-2-methyl-propanamide: a selective androgen receptor modulator for hormonal male contraception","volume":"150","author":"Jones","year":"2009","journal-title":"Endocrinology"},{"key":"10.1016\/j.xfnr.2020.11.001_bib63","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1124\/jpet.104.075424","article-title":"A selective androgen receptor modulator for hormonal male contraception","volume":"312","author":"Chen","year":"2005","journal-title":"J Pharmacol Exp Therap"},{"key":"10.1016\/j.xfnr.2020.11.001_bib64","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0189480","article-title":"Amelioration of sexual behavior and motor activity deficits in a castrated rodent model with a selective androgen receptor modulator SARM-2f","volume":"12","author":"Morimoto","year":"2017","journal-title":"PloS One"},{"key":"10.1016\/j.xfnr.2020.11.001_bib65","first-page":"232","article-title":"Selective androgen receptor modulators (SARMs) as function promoting therapies","volume":"12","author":"Bhasin","year":"2009","journal-title":"Curr Opin Clin Nutr Metab Care"},{"key":"10.1016\/j.xfnr.2020.11.001_bib66","doi-asserted-by":"crossref","first-page":"2681","DOI":"10.1007\/s00018-019-03101-9","article-title":"The roles and mechanisms of Leydig cells and myoid cells in regulating spermatogenesis","volume":"76","author":"Zhou","year":"2019","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.xfnr.2020.11.001_bib67","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1095\/biolreprod65.3.660","article-title":"Differentiation of the adult Leydig cell population in the postnatal testis","volume":"65","author":"Mendis-Handagama","year":"2001","journal-title":"Biol Reprod"},{"key":"10.1016\/j.xfnr.2020.11.001_bib68","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.mce.2009.01.023","article-title":"Leydig cells: from stem cells to aging","volume":"306","author":"Chen","year":"2009","journal-title":"Mol Cell Endocrinol"},{"key":"10.1016\/j.xfnr.2020.11.001_bib69","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1002\/bdrc.20192","article-title":"Stem Leydig cells: from fetal to aged animals","volume":"90","author":"Chen","year":"2010","journal-title":"Birth Defects Res C Embryo Today"},{"key":"10.1016\/j.xfnr.2020.11.001_bib70","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1002\/sctm.18-0069","article-title":"Subcutaneous Leydig stem cell autograft: a promising strategy to increase serum testosterone","volume":"8","author":"Arora","year":"2019","journal-title":"Stem Cells Transl Med"},{"key":"10.1016\/j.xfnr.2020.11.001_bib71","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/0010-7824(75)90111-0","article-title":"Leydig cells","volume":"11","author":"Neaves","year":"1975","journal-title":"Contraception"},{"key":"10.1016\/j.xfnr.2020.11.001_bib72","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.exger.2015.02.014","article-title":"Leydig cell aging and hypogonadism","volume":"68","author":"Beattie","year":"2015","journal-title":"Exp Gerontol"},{"key":"10.1016\/j.xfnr.2020.11.001_bib73","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1111\/andr.12459","article-title":"Leydig cell insufficiency in hypospermatogenesis: a paracrine effect of activin-inhibin signaling?","volume":"6","author":"Winters","year":"2018","journal-title":"Andrology"},{"key":"10.1016\/j.xfnr.2020.11.001_bib74","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1038\/cr.2014.149","article-title":"Characterization of Nestin-positive stem Leydig cells as a potential source for the treatment of testicular Leydig cell dysfunction","volume":"24","author":"Jiang","year":"2014","journal-title":"Cell Res"},{"key":"10.1016\/j.xfnr.2020.11.001_bib75","doi-asserted-by":"crossref","first-page":"e3123","DOI":"10.1038\/cddis.2017.531","article-title":"Transplanted human p75-positive stem Leydig cells replace disrupted Leydig cells for testosterone production","volume":"8","author":"Zhang","year":"2017","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.xfnr.2020.11.001_bib76","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/j.drudis.2015.06.007","article-title":"Therapeutic transdermal drug innovation from 2000 to\u00a02014: current status and outlook","volume":"20","author":"Walter","year":"2015","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.xfnr.2020.11.001_bib77","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1001\/jama.2014.17334","article-title":"Testosterone replacement therapy faces FDA scrutiny","volume":"313","author":"Garnick","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.xfnr.2020.11.001_bib78","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1093\/humupd\/dmh035","article-title":"Testosterone replacement therapy: current trends and future directions","volume":"10","author":"Nieschlag","year":"2004","journal-title":"Hum Reprod Update"},{"key":"10.1016\/j.xfnr.2020.11.001_bib79","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1177\/2042098614548680","article-title":"Adverse effects of testosterone replacement therapy: an update on the evidence and controversy","volume":"5","author":"Grech","year":"2014","journal-title":"Ther Adv Drug Saf"},{"key":"10.1016\/j.xfnr.2020.11.001_bib80","doi-asserted-by":"crossref","first-page":"68","DOI":"10.12688\/f1000research.10102.1","article-title":"Treatment of hypogonadism: current and future therapies","volume":"6","author":"Thirumalai","year":"2017","journal-title":"F1000Res"},{"key":"10.1016\/j.xfnr.2020.11.001_bib81","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1185\/030079904125003494","article-title":"Short-term pharmacokinetic comparison of a novel testosterone buccal system and a testosterone gel in testosterone deficient men","volume":"20","author":"Dobs","year":"2004","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.xfnr.2020.11.001_bib82","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1210\/jc.2003-032006","article-title":"Long-term testosterone gel (AndroGel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypogonadal men","volume":"89","author":"Wang","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.xfnr.2020.11.001_bib83","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1111\/j.1743-6109.2005.20231.x","article-title":"Comparison of the steady-state pharmacokinetics, metabolism, and variability of a transdermal testosterone patch versus a transdermal testosterone gel in hypogonadal men","volume":"2","author":"Mazer","year":"2005","journal-title":"J Sex Med"},{"key":"10.1016\/j.xfnr.2020.11.001_bib84","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1210\/jc.2002-021058","article-title":"AA2500 testosterone gel normalizes androgen levels in aging males with improvements in body composition and sexual function","volume":"88","author":"Steidle","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.xfnr.2020.11.001_bib85","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/sj.ijir.3901618","article-title":"Efficacy of changing testosterone gel preparations (Androgel or Testim) among suboptimally responsive hypogonadal men","volume":"20","author":"Grober","year":"2008","journal-title":"Int J Impot Res"}],"container-title":["F&amp;S Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666571920300098?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666571920300098?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T02:13:43Z","timestamp":1763000023000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666571920300098"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":85,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["S2666571920300098"],"URL":"https:\/\/doi.org\/10.1016\/j.xfnr.2020.11.001","relation":{},"ISSN":["2666-5719"],"issn-type":[{"value":"2666-5719","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Exogenous testosterone replacement therapy versus raising endogenous testosterone levels: current and future prospects","name":"articletitle","label":"Article Title"},{"value":"F&S Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xfnr.2020.11.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Published by Elsevier Inc. on behalf of American Society for Reproductive Medicine.","name":"copyright","label":"Copyright"}]}}